“The drug is already in a high degree of readiness.
We are already entering clinical trials in the near future.
I hope that ... in the next ... months - 3-5 months, you can get approval, "- quotes TASS as saying Logunov.
According to him, currently in the center.
There are two directions of Gamaleya, one of them is the direction with monoclonal antibodies.
“Another area is, of course, chemotherapy, chemicals,” the scientist noted.
He noted that by the end of 2022, Russia will be able to obtain registration of this drug.